Image-Based High-Content Analysis, Stem Cells and Nanomedicines: A Novel Strategy for Drug Discovery

2016 ◽  
pp. 663-686
ChemPhysChem ◽  
2011 ◽  
Vol 12 (3) ◽  
pp. 609-626 ◽  
Author(s):  
Sunil Kumar ◽  
Dominic Alibhai ◽  
Anca Margineanu ◽  
Romain Laine ◽  
Gordon Kennedy ◽  
...  

2016 ◽  
Vol 6 (1) ◽  
pp. 109-120 ◽  
Author(s):  
Jared Carlson-Stevermer ◽  
Madelyn Goedland ◽  
Benjamin Steyer ◽  
Arezoo Movaghar ◽  
Meng Lou ◽  
...  

2013 ◽  
Vol 7 (4) ◽  
pp. e2154 ◽  
Author(s):  
Nathalie Aulner ◽  
Anne Danckaert ◽  
Eline Rouault-Hardoin ◽  
Julie Desrivot ◽  
Olivier Helynck ◽  
...  

2019 ◽  
Vol 24 (6) ◽  
pp. 615-627 ◽  
Author(s):  
Tijmen H. Booij ◽  
Leo S. Price ◽  
Erik H. J. Danen

The introduction of more relevant cell models in early preclinical drug discovery, combined with high-content imaging and automated analysis, is expected to increase the quality of compounds progressing to preclinical stages in the drug development pipeline. In this review we discuss the current switch to more relevant 3D cell culture models and associated challenges for high-throughput screening and high-content analysis. We propose that overcoming these challenges will enable front-loading the drug discovery pipeline with better biology, extracting the most from that biology, and, in general, improving translation between in vitro and in vivo models. This is expected to reduce the proportion of compounds that fail in vivo testing due to a lack of efficacy or to toxicity.


PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e102678 ◽  
Author(s):  
Albert H. Gough ◽  
Ning Chen ◽  
Tong Ying Shun ◽  
Timothy R. Lezon ◽  
Robert C. Boltz ◽  
...  

2016 ◽  
Vol 24 ◽  
pp. S229-S230
Author(s):  
Jared Carlson-Stevermer ◽  
Madelyn Goedland ◽  
Benjamin Steyer ◽  
Arezoo Movaghar ◽  
Meng Lou ◽  
...  

2008 ◽  
Vol 11 (3) ◽  
pp. 216-230 ◽  
Author(s):  
Philip Denner ◽  
Janine Schmalowsky ◽  
Stefan Prechtl

Sign in / Sign up

Export Citation Format

Share Document